{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:19:50Z","timestamp":1787501990497,"version":"build-2736575974"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare yet life-threatening severe cutaneous adverse drug reactions (SCARs), characterized by high mortality and substantial morbidity risks. Identifying potential high-risk drugs associated with SJS\/TEN is crucial for guiding clinical preventive interventions, enabling early detection, and enhancing risk management. With the rapid advancement of data science, adverse drug reaction (ADR) database mining has emerged as a powerful tool for systematically investigating the drug-SJS\/TEN association, effectively overcoming the limitations of traditional case reports and small-sample studies regarding data scale and conclusion generalizability. This review summarizes recent advances in identifying potential high-risk drugs for SJS\/TEN based on ADR database mining, with all included studies retrieved from peer-reviewed journals and strictly focused on SJS\/TEN. We classify and discuss the major potential high-risk drug categories, including antibiotics, antiepileptics, allopurinol, nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), immune checkpoint inhibitors (ICIs), novel antiandrogens, carbonic anhydrase inhibitors, antivirals, and others. We also summarize their associated genetic susceptibilities, median onset times, and underlying mechanisms. These findings provide valuable references for enhancing medication safety and mitigating severe adverse drug reactions in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2026.1775888","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:42:16Z","timestamp":1780378936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining"],"prefix":"10.3389","volume":"17","author":[{"given":"Houci","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the stevens-johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/1346-8138.12674","article-title":"Immunological response in stevens-johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Abe","year":"2015","journal-title":"J. Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2125.2010.03764.x","article-title":"Delayed drug hypersensitivity: models of T-cell stimulation","volume":"71","author":"Adam","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hon.1000","article-title":"Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options","volume":"30","author":"Allegra","year":"2012","journal-title":"Hematol. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.eplepsyres.2008.04.003","article-title":"Cross-reactivity pattern of rash from current aromatic antiepileptic drugs","volume":"80","author":"Alvestad","year":"2008","journal-title":"Epilepsy Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/epi.12564","article-title":"Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions","volume":"55","author":"Amstutz","year":"2014","journal-title":"Epilepsia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e21864","DOI":"10.7759\/cureus.21864","article-title":"Methazolamide associated Stevens-Johnson Syndrome\/Toxic epidermal necrolysis in a female of caucasian descent","volume":"14","author":"Baluch","year":"2022","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/postgradmedj-2020-138326","article-title":"Terbinafine-induced steven-Johnson syndrome and toxic epidermal necrolysis (SJS\/TEN) overlap","volume":"97","author":"Banik","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"B11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch. Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/j.jped.2025.101455","article-title":"Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: age-stratified insights from the FAERS database","volume":"8","author":"Bayram-Ozgur","year":"2025","journal-title":"J. Pediatr. Rio J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/bjd.14201","article-title":"Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds","volume":"174","author":"Bell\u00f3n","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/cts.13291","article-title":"Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: an updated meta-analysis","volume":"15","author":"Biswas","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2217\/pgs.14.65","article-title":"Pharmacogenetics of antiepileptic drug-induced hypersensitivity","volume":"15","author":"Bloch","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaip.2014.10.002","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system","volume":"3","author":"Blumenthal","year":"2015","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug administration adverse event reporting system","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/jamadermatol.2025.4240","article-title":"Stevens-johnson Syndrome\/toxic epidermal necrolysis (SJS\/TEN) survivor study collaborators. HLA-B*58:01 and risk of allopurinol-induced severe cutaneous adverse reactions in the US","volume":"161","author":"Campbell","year":"2025","journal-title":"JAMA Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/00185787251337610","article-title":"Pharmacovigilance and Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN): 55 years of retrospective analysis of the FDA adverse event reporting system (FAERS) database","volume":"30","author":"Castellana","year":"2025","journal-title":"Hosp. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1111\/epi.17726","article-title":"Impact on carbamazepine usage and cutaneous adverse reactions before and after the reimbursement of HLA-B*1502 genotyping in Taiwan, 2000-2017: a nationwide longitudinal study","volume":"64","author":"Chang","year":"2023","journal-title":"Epilepsia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70132","DOI":"10.1002\/kjm2.70132","article-title":"Fatal pembrolizumab-induced stevens-Johnson Syndrome\/toxic epidermal necrolysis in a patient with advanced lung adenocarcinoma","volume":"23","author":"Chang","year":"2025","journal-title":"Kaohsiung J. Med. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and steven\u2013johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv. Wound Care New Rochelle."},{"key":"B26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2105\/ajph.93.3.489","article-title":"Outbreak of Stevens-Johnson syndrome\/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan","volume":"93","author":"Chen","year":"2003","journal-title":"Am. J. Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1212\/WNL.0000000000001034","article-title":"Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions","volume":"83","author":"Chen","year":"2014","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/bjd\/ljad234","article-title":"Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens-Johnson syndrome\/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019","volume":"189","author":"Chiu","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br. J. Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/archdischild-2013-304767","article-title":"Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore","volume":"99","author":"Chong","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jdermsci.2012.04.002","article-title":"Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis","volume":"66","author":"Chung","year":"2012","journal-title":"J. Dermatol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and Nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1744-313X.2011.01011.x","article-title":"A study of HLA class I and class II 4-digit allele level in stevens-johnson syndrome and toxic epidermal necrolysis","volume":"38","author":"Cristallo","year":"2011","journal-title":"Int. J. Immunogenet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"031501","DOI":"10.1063\/5.0143311","article-title":"Advances in point-of-care genetic testing for personalized medicine applications","volume":"17","author":"de Olazarra","year":"2023","journal-title":"Biomicrofluidics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1468-1331.2011.03361.x","article-title":"A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity","volume":"18","author":"Depondt","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an update","volume":"16","author":"Dodiuk-Gad","year":"2015","journal-title":"Am. J. Clin. Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","article-title":"Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore","volume":"79","author":"Dong","year":"2012","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3332\/ecancer.2020.1010","article-title":"Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin","volume":"14","author":"Eichhoff","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.toxrep.2024.02.006","article-title":"NSAID (nonsteroidal anti-inflammatory drugs) induced Stevens Johnson syndrome in a 50-year-old woman: a case study","volume":"12","author":"Faraji","year":"2024","journal-title":"Toxicol. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2147\/CCID.S422928","article-title":"Causes of drug-induced severe cutaneous adverse reaction epidermal Necrolysis (EN): an analysis using FDA Adverse Event reporting system (FAERS) database","volume":"16","author":"Fei","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jid.2017.12.015","article-title":"Antibiotic drug use and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based case-control study","volume":"138","author":"Frey","year":"2018","journal-title":"J. Invest. Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40264-018-0711-x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case-control study","volume":"42","author":"Frey","year":"2019","journal-title":"Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1046\/j.1365-2222.2003.01718.x","article-title":"Mechanisms in cutaneous drug hypersensitivity reactions","volume":"33","author":"Friedmann","year":"2003","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1016\/j.jaip.2023.07.012","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antibiotic use: a case-crossover study","volume":"11","author":"Fukasawa","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1111\/jdv.18550","article-title":"Store and forward teledermatology for epidermal necrolysis management: experience of a french reference centre","volume":"37","author":"Giraud-Kerleroux","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. Jeadv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br. J. Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"D783","DOI":"10.1093\/nar\/gkz1029","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamadermatol.2024.1037","article-title":"Economic evaluation of HLA-B*15:02 genotyping for Asian Australian patients with epilepsy","volume":"160","author":"Gu","year":"2024","journal-title":"JAMA Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J. Am. Acad. Dermatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-612","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding stevens-johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Research"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","article-title":"Stevens\u2013johnson syndrome and toxic epidermal necrolysis: updates in pathophysiology and management","volume":"137","author":"Hasegawa","year":"2024","journal-title":"Chin. Med. J. Engl."},{"key":"B60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.15036\/arerugi.74.285","article-title":"A case of pediatritic toxic epidermal necrosis triggerd by over-the-counter eye drops","volume":"74","author":"Hashimoto","year":"2025","journal-title":"Arerugi"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/epi.12655","article-title":"Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in Chinese Han patients with epilepsy","volume":"55","author":"He","year":"2014","journal-title":"Epilepsia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.seizure.2024.03.009","article-title":"Real-world safety of Levetiracetam: mining and analysis of its adverse drug reactions based on FAERS database","volume":"117","author":"He","year":"2024","journal-title":"Seizure"},{"key":"B63","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1399-0039.2007.00982.x","article-title":"HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam","volume":"71","author":"Hoa","year":"2008","journal-title":"Tissue Antigens"},{"key":"B64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40261-019-00754-z","article-title":"Adverse cutaneous drug reactions associated with Old- and New- generation antiepileptic drugs using the Japanese pharmacovigilance database","volume":"39","author":"Hosohata","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"B65","doi-asserted-by":"publisher","first-page":"597761","DOI":"10.3389\/fimmu.2021.597761","article-title":"The roles of immunoregulatory networks in severe drug hypersensitivity","volume":"12","author":"Hsu","year":"2021","journal-title":"Front. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"644871","DOI":"10.3389\/fmed.2021.644871","article-title":"Associations between Stevens-Johnson Syndrome and infection: overview of pharmacoepidemiological studies","volume":"8","author":"Imatoh","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CMR.0000000000000819","article-title":"Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases","volume":"32","author":"Ingen-Housz-Oro","year":"2022","journal-title":"Melanoma Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jad.2015.03.018","article-title":"Association between HLA-DRB1*0405, -DQB1*0401 and -DQA1*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan","volume":"179","author":"Ito","year":"2015","journal-title":"J. Affect Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/jdv.17980","article-title":"Unique motif shared by HLA-B*59:01 and HLA-B*55:02 is associated with methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"36","author":"Jiang","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e87202","DOI":"10.7759\/cureus.87202","article-title":"Fatal case of Stevens-Johnson Syndrome\/Toxic epidermal necrolysis induced by doxycycline or flucloxacillin in a 77-Year-Old woman: a rare but serious adverse drug reaction","volume":"17","author":"Johnson","year":"2025","journal-title":"Cureus"},{"key":"B74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2217\/pgs.13.180","article-title":"Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects","volume":"14","author":"Kaniwa","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B78","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/1346-8138.16972","article-title":"Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: a review of the literature","volume":"51","author":"Katsuta","year":"2024","journal-title":"J. Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2217\/pgs.10.54","article-title":"HLA-B*5901 is strongly associated with Methazolamide-Induced Stevens\u2013Johnson Syndrome\/Toxic epidermal necrolysis","volume":"11","author":"Kim","year":"2010","journal-title":"Pharmacogenomics"},{"key":"B80","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/ph14111077","article-title":"A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine","volume":"14","author":"Kloypan","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/00002018-199921060-00005","article-title":"Anticonvulsant hypersensitivity syndrome: incidence, prevention and management","volume":"21","author":"Knowles","year":"1999","journal-title":"Drug Saf."},{"key":"B83","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.gmg.2025.100054","article-title":"A review of the immunogenetics of stevens-johnson syndrome and toxic epidermal necrolysis","volume":"12","author":"Kocaaga","year":"2025","journal-title":"Glob. Med. Genet."},{"key":"B84","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"B85","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4168\/aair.2015.7.4.312","article-title":"Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice?","volume":"7","author":"Kowalski","year":"2015","journal-title":"Allergy Asthma Immunol. Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"898790","DOI":"10.3389\/fmed.2022.898790","article-title":"High grade dermatologic adverse events associated with immune checkpoint blockade for cancer","volume":"9","author":"Kuo","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/PGPM.S129908","article-title":"CYP2C19*2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Laska","year":"2017","journal-title":"Pharmgenomics Pers. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1399-0039.2005.00386.x","article-title":"Allelic and haplotypic diversity of HLA\u2010A, \u2010B, \u2010C, \u2010DRB1, and \u2010DQB1 genes in the Korean population","volume":"65","author":"Lee","year":"2005","journal-title":"Tissue Antigens"},{"key":"B89","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00130832-200410000-00013","article-title":"The immunological and clinical spectrum of delayed drug-induced exanthems","volume":"4","author":"Lerch","year":"2004","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B91","first-page":"50","article-title":"HLA-B gene polymorphism detected by high-resolution sequence-based typing in Guangdong Han populations","volume":"23","author":"Li","year":"2006","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2442023","article-title":"Vancomycin and linezolid: severe cutaneous adverse reactions to drugs","volume":"22","author":"Li","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3760\/cma.j.cn112140-20240813-00577","article-title":"Deflazacort-induced Steven-Johnson syndrome: a case report and literature review","volume":"62","author":"Li","year":"","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B94","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00403-025-04107-z","article-title":"Potential drugs associated with toxic epidermal necrolysis: a disproportionality analysis based on the FAERS database (2004-2024)","volume":"317","author":"Li","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1445-5994.2005.00790.x","article-title":"Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study","volume":"35","author":"Lin","year":"2005","journal-title":"Intern. Med. J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/all.13235","article-title":"Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study","volume":"73","author":"Lin","year":"2018","journal-title":"Allergy"},{"key":"B97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1124\/dmd.107.015271","article-title":"Possible bioactivation pathways of lamotrigine","volume":"35","author":"Lu","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"B100","doi-asserted-by":"publisher","first-page":"bcr2014209102","DOI":"10.1136\/bcr-2014-209102","article-title":"Toxic epidermal necrolysis with the use of tamoxifen","volume":"2015","author":"Madabhavi","year":"2015","journal-title":"BMJ Case Rep."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.4088\/jcp.v65n1219a","article-title":"A cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis","volume":"65","author":"Majeres","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"B102","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/s0140-6736(02)07873-x","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"567048","DOI":"10.3389\/fphar.2020.567048","article-title":"Diagnostic Test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines","volume":"11","author":"Manson","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/17512433.2023.2294002","article-title":"Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database","volume":"17","author":"Mao","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1067\/mjd.2001.101885","article-title":"Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine","volume":"44","author":"Metry","year":"2001","journal-title":"J. Am. Acad. Dermatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"B112","first-page":"2234","article-title":"The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective","volume":"30","author":"Mockenhaupt","year":"2003","journal-title":"J. Rheumatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series","volume":"83","author":"Molina","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B116","volume-title":"Otc monographs @ FDA","year":"2025"},{"key":"B117","doi-asserted-by":"publisher","first-page":"20420986241312484","DOI":"10.1177\/20420986241312484","article-title":"Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report","volume":"16","author":"Mor\u00e1n-Mari\u00f1os","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.05.25323441","article-title":"Characterization of demographics, drug latency, and mortality of severe cutaneous adverse reactions in an FDA pharmacovigilance database","volume":"2025","author":"Mukherjee","year":"","journal-title":"medRxiv."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1542\u20131545","DOI":"10.1001\/jamaoncol.2025.4349","article-title":"Immune checkpoint inhibitors as independent and synergistic drivers of SJS\/TEN","volume":"11","author":"Mukherjee","year":"","journal-title":"JAMA Oncol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/clinids\/23.3.640","article-title":"Fatal toxic epidermolysis induced by zidovudine","volume":"23","author":"Murri","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1067\/mai.2003.1507","article-title":"Characterization of drug-specific T cells in lamotrigine hypersensitivity","volume":"111","author":"Naisbitt","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"100480","DOI":"10.1016\/j.dmpk.2022.100480","article-title":"Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions","volume":"47","author":"Nakkam","year":"2022","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","article-title":"Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions","volume":"136","author":"Ng","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","article-title":"HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese","volume":"5","author":"Nguyen","year":"2015","journal-title":"Asia. Pac. Allergy"},{"key":"B125","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.waojou.2019.100037","article-title":"Developing pharmacogenetic screening methods for an emergent country: vietnam","volume":"12","author":"Nguyen","year":"2019","journal-title":"World Allergy Organ J."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamadermatol.2021.3450","article-title":"Postmarketing cases of enfortumab vedotin\u2013associated skin reactions reported as Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"872854","DOI":"10.3389\/fphar.2022.872854","article-title":"Stevens-johnson syndrome following vancomycin and linezolid: a real-world analysis of post-marketing surveillance data","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/FPC.0b013e3283390666","article-title":"An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe","volume":"20","author":"Orkin","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B129","doi-asserted-by":"publisher","first-page":"A118","DOI":"10.1016\/j.fander.2021.09.543","article-title":"Toxidermies bulleuses graves induites par les inhibiteurs de checkpoint: \u00e9tude r\u00e9trospective multicentrique internationale de 29 patients","volume":"1","author":"Oro","year":"2021","journal-title":"Ann. Dermatol. V\u00e9n\u00e9r\u00e9ol. - FMC"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4168\/aair.2019.11.5.709","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs: a nationwide registry-based study in Korea","volume":"11","author":"Park","year":"2019","journal-title":"Allergy Asthma Immunol. Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/0140-6736(92)92740-7","article-title":"Didanosine as probable cause of stevens-johnson syndrome","volume":"340","author":"Parneix-Spake","year":"1992","journal-title":"Lancet"},{"key":"B133","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jtos.2025.06.004","article-title":"Attribution of causality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"38","author":"Parvathaneni","year":"2025","journal-title":"Ocul. Surf."},{"key":"B134","doi-asserted-by":"publisher","first-page":"02391","DOI":"10.1016\/j.jaad.2025.03.106","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of immune checkpoint inhibitors: a disproportionality analysis using the food and drug administration adverse event reporting system database","author":"Pathak","year":"2025","journal-title":"J. Am. Acad. Dermatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0300-483x(02)00254-8","article-title":"Modes of presentation of chemical neoantigens to the immune system","author":"Pichler","year":"2002","journal-title":"Toxicology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.seizure.2025.01.002","article-title":"Post-marketing safety of antiseizure medications: focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"125","author":"Qian","year":"2025","journal-title":"Seizure"},{"key":"B137","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.phrs.2016.11.027","article-title":"Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS\/TEN are different from those found for the same AED-induced DRESS in the Spanish population","volume":"115","author":"Ram\u00edrez","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B138","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch. Dermatol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2133.2012.10921.x","article-title":"Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome","volume":"167","author":"Saito","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"245ra95","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.3748\/wjg.15.4449","article-title":"Stevens-Johnson syndrome complicating adalimumab therapy in Crohn\u2019s disease","volume":"15","author":"Salama","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J. Invest Dermatol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"565296","DOI":"10.1155\/2014\/565296","article-title":"Distribution of HLA-a, -B, and -C alleles and HLA\/KIR combinations in han population in China","volume":"2014","author":"Shen","year":"2014","journal-title":"J. Immunol. Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1742-7843.2012.00868.x","article-title":"Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?","volume":"111","author":"Shi","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1212\/WNL.0000000000004008","article-title":"HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions","volume":"88","author":"Shi","year":"2017","journal-title":"Neurology"},{"key":"B146","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archopht.1997.01100150552021","article-title":"Stevens-Johnson syndrome induced by methazolamide treatment","volume":"115","author":"Shirato","year":"1997","journal-title":"Arch. Ophthalmol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/ijd.12651","article-title":"Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01","volume":"54","author":"Shu","year":"2015","journal-title":"Int. J. Dermatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1440-1762.2000.00353.x","article-title":"Quality use of allopurinol in the elderly","volume":"20","author":"Smith","year":"2000","journal-title":"J. Qual. Clin. Pract."},{"key":"B149","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (*) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/cpt.1915","article-title":"Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes","volume":"108","author":"Sukasem","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11596-014-1247-7","article-title":"Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China","volume":"34","author":"Sun","year":"2014","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archderm.134.9.1108","article-title":"Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome","volume":"134","author":"Suzuki","year":"1998","journal-title":"Arch. Dermatol."},{"key":"B153","first-page":"139","article-title":"Report of the Japanese central bone marrow data center","author":"Tanaka","year":"1996","journal-title":"Clin. Transpl."},{"key":"B154","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41397-018-0052-2","article-title":"Association between HLA-B*5901 and methazolamide-induced stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"19","author":"Tangamornsuksan","year":"2019","journal-title":"Pharmacogenomics J."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"e0136141","DOI":"10.1371\/journal.pone.0136141","article-title":"The absence of CYP3A5*3 is a protective factor to anticonvulsants hypersensitivity reactions: a case-control study in Brazilian subjects","volume":"10","author":"Tanno","year":"2015","journal-title":"PLoS One"},{"key":"B157","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"B158","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"B159","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1080\/00365549850161322","article-title":"Stevens-Johnson syndrome caused by indinavir","volume":"30","author":"Teira","year":"1998","journal-title":"Scand. J. Infect. Dis."},{"key":"B160","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/FPC.0000000000000531","article-title":"Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"34","author":"Tham","year":"2024","journal-title":"Pharmacogenet Genomics"},{"key":"B161","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1046\/j.1365-2133.2002.302711.x","article-title":"1 randomized controlled trial of short bursts of a potent topical corticosteroid versus more prolonged use of a mild preparation for children with atopic eczema","volume":"146","author":"Thomas","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1258\/ijsa.2012.012102","article-title":"HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?","volume":"24","author":"To","year":"2013","journal-title":"Int. J. STD AIDS"},{"key":"B163","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"B164","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjd.18294","article-title":"Individual- and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012-2016","volume":"182","author":"Traikia","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"B166","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ccr3.1288","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis associated with zonisamide","volume":"6","author":"Vivar","year":"2018","journal-title":"Clin. Case Rep."},{"key":"B167","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.seizure.2010.09.003","article-title":"Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population","volume":"19","author":"Wang","year":"2010","journal-title":"Seizure"},{"key":"B168","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.seizure.2011.02.003","article-title":"Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland","volume":"20","author":"Wang","year":"","journal-title":"Seizure"},{"key":"B169","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.eplepsyres.2011.02.005","article-title":"Influence of chemical structure on skin reactions induced by antiepileptic drugs--the role of the aromatic ring","volume":"94","author":"Wang","year":"","journal-title":"Epilepsy Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.eplepsyres.2017.05.015","article-title":"Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis","volume":"135","author":"Wang","year":"2017","journal-title":"Epilepsy Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.clinthera.2024.09.014","article-title":"Toxic epidermal necrolysis observed in a patient with the HLA-B*1502 treated with Levofloxacin","volume":"46","author":"Wang","year":"2024","journal-title":"Clin. Ther."},{"key":"B172","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0140-6736(98)24008-6","article-title":"Nevirapine-associated Stevens-Johnson syndrome","volume":"351","author":"Warren","year":"1998","journal-title":"Lancet"},{"key":"B173","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","article-title":"Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review","volume":"81","author":"Weinkle","year":"2019","journal-title":"J. Am. Acad. Dermatol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10637-024-01499-z","article-title":"Clinical features, treatment, and prognosis of pembrolizumab-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"43","author":"Wu","year":"2025","journal-title":"Invest. New Drugs"},{"key":"B175","doi-asserted-by":"publisher","first-page":"107524","DOI":"10.1016\/j.ijantimicag.2025.107524","article-title":"Association of antibiotics with Stevens-Johnson syndrome and toxic epidermal necrolysis: a real-world pharmacovigilance study","volume":"66","author":"Yan","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B176","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/tpj.2015.25","article-title":"HLA-B*59:01: a marker for Stevens-Johnson syndrome\/toxic epidermal necrolysis caused by methazolamide in Han Chinese","volume":"16","author":"Yang","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B177","doi-asserted-by":"crossref","DOI":"10.22541\/au.176645178.85835134\/v1","article-title":"Research progress on high-risk drugs for stevens-johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining","author":"Yang","year":""},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1555955","article-title":"Risk of medication-induced lactic acidosis and hyperlactatemia: a pharmacovigilance study of the United States food and drug Administration\u2019s adverse event reporting system database","author":"Yang","year":"","journal-title":"Front. Pharmacol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.seizure.2010.11.014","article-title":"Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population","volume":"20","author":"Yun","year":"2011","journal-title":"Seizure"},{"key":"B180","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00228-011-1009-4","article-title":"Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients","volume":"67","author":"Zhang","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.70059","article-title":"Severe cutaneous adverse reactions associated with novel antiandrogens: a disproportionality analysis of three databases","volume":"30","author":"Zhu","year":"2025","journal-title":"Int. J. Cancer"},{"key":"B182","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-3-319-74588-6_195","article-title":"Stevens\u2013johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)","volume":"9","author":"Zimmerman","year":"2019","journal-title":"Oncol. Crit. Care"},{"key":"B183","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.seizure.2012.09.005","article-title":"Stevens\u2013Johnson syndrome induced by levetiracetam","volume":"21","author":"Zou","year":"2012","journal-title":"Seizure"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1775888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:42:20Z","timestamp":1780378940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1775888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":183,"alternative-id":["10.3389\/fphar.2026.1775888"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1775888","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.176645178.85835134\/v1","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1775888"}}